Skip to main content

Loading market data...

ALKS

Alkermes plc

NASDAQ • United states

$42.97

+$1.75

(+4.25%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Alkermes plc (ALKS)

Unavailable

Quotes may be delayed

$7.21B

Market Cap

2,713,433

Volume

109.0

P/E Ratio

Unavailable

Div Yield

Alkermes plc Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: CONNAUGHT HOUSE, DUBLIN 4, L2
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

21 Sep 2026

Alkermes plc reported Regulation FD disclosure

Alkermes plc filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

16 Sep 2026

Alkermes plc reported A director or senior management change or compensation event

Alkermes plc filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.

12 Aug 2026

Alkermes plc reported A material agreement

Alkermes plc filed an 8-K covering a material agreement, supporting financial statements or exhibits.

29 Jul 2026

Alkermes plc securities registration filing

Alkermes plc filed a registration or prospectus document concerning securities.

28 Jul 2026

Alkermes plc filed Form 10-Q

Alkermes plc submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$511.53M

Total assets (USD)$4.39B

Total liabilities (USD)$2.58B

Shareholders' equity (USD)$1.81B

Long-term debt (USD)$1.48B

Debt due within a year (USD)$26.50M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$496.01M	$18.35M	$501,000	$0.00	10-Q · 28 Jul 2026
Q1 2026	$392.91M	−$48.28M	−$66.48M	−$0.40	10-Q · 5 May 2026
Q4 2025	$384.55M	$58.10M	$49.38M	Unavailable	10-K · 25 Feb 2026
Q3 2025	$394.19M	$89.08M	$82.76M	$0.49	10-Q · 28 Oct 2025
Q2 2025	$390.66M	$92.98M	$87.10M	$0.52	10-Q · 29 Jul 2025
Q1 2025	$306.51M	$13.79M	$22.46M	$0.13	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $58.77

36.8% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

3

📉

Sell

1

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 12:49 UTC Targets range 38.00–83.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

8

Oct 2026

Reed Joshua

SVP, Chief Financial Officer

Option exercise

Unavailable per share

9,164 shares

8

Oct 2026

Reed Joshua

SVP, Chief Financial Officer

Tax withholding

$40.11 per share

4,069 shares

2

Oct 2026

Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Open-market sale

$41.03 per share

2,034 shares

3

Sep 2026

Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Open-market sale

$48.01 per share

2,034 shares

1

Sep 2026

Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Option exercise

$24.59 per share

5,000 shares

1

Sep 2026

Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Open-market sale

$46.99 per share

9,000 shares

17

Aug 2026

Nichols Christian Todd

SVP, Chief Commercial Officer

Open-market sale

$49.23 per share

7,576 shares

3

Aug 2026

snyderman nancy lynn MD

Director

Option exercise

$46.72 per share

44,472 shares

3

Aug 2026

snyderman nancy lynn MD

Director

Open-market sale

$50.35 per share

44,472 shares

Top Shareholders

Blackrock, Inc.

29,235,739 shares

3.254% change

6/30/2026

Vanguard Group Inc

23,872,145 shares

0.363% change

12/31/2025

Baker Bros. Advisors Lp

10,012,267 shares

0% change

6/30/2026

Vanguard Portfolio Management Llc

9,490,818 shares

-0.213% change

6/30/2026

State Street Corp

9,160,575 shares

-3.219% change

6/30/2026

Vanguard Capital Management Llc

7,515,025 shares

1.18% change

6/30/2026

Price T Rowe Associates Inc /Md/

6,737,328 shares

44.436% change

6/30/2026

Renaissance Technologies Llc

6,460,928 shares

4.878% change

6/30/2026

Geode Capital Management, Llc

4,477,876 shares

7.068% change

6/30/2026

Dimensional Fund Advisors Lp

4,194,873 shares

-7.242% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 12:49 UTC· 1 day ago

Research coverage and investment tools

Alkermes plc (ALKS) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$42.97 on 19 Oct 2026. That is 56% of the way from its 52-week low of US$27.00 to its 52-week high of US$55.67. Its market capitalisation was US$7.21 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$496.01M	$18.35M	$501,000	$0.00	—	3.7%	$137.04M	10-Q · 28 Jul 2026 (opens in a new tab)
Q1 2026	$392.91M	−$48.28M	−$66.48M	−$0.40	—	-12.3%	−$169.83M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$384.55M	$58.10M	$49.38M	Unavailable	—	15.1%	$170.09M	10-K · 25 Feb 2026 (opens in a new tab)
Q3 2025	$394.19M	$89.08M	$82.76M	$0.49	—	22.6%	$84.36M	10-Q · 28 Oct 2025 (opens in a new tab)
Q2 2025	$390.66M	$92.98M	$87.10M	$0.52	—	23.8%	$137.19M	10-Q · 29 Jul 2025 (opens in a new tab)
Q1 2025	$306.51M	$13.79M	$22.46M	$0.13	—	4.5%	$88.70M	10-Q · 1 May 2025 (opens in a new tab)

Cash and equivalents: $511.53M
Total assets: $4.39B
Total liabilities: $2.58B
Shareholders' equity: $1.81B
Long-term debt: $1.48B
Debt due within a year: $26.50M

8-K · 21 Sep 2026

Alkermes plc reported Regulation FD disclosure (opens in a new tab)

Alkermes plc filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.
8-K · 16 Sep 2026 · Management change

Alkermes plc reported A director or senior management change or compensation event (opens in a new tab)

Alkermes plc filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.
8-K · 12 Aug 2026 · Material agreement Signed

Alkermes plc reported A material agreement (opens in a new tab)

Alkermes plc filed an 8-K covering a material agreement, supporting financial statements or exhibits.
S-8 · 29 Jul 2026

Alkermes plc securities registration filing (opens in a new tab)

Alkermes plc filed a registration or prospectus document concerning securities.
10-Q · 28 Jul 2026

Alkermes plc filed Form 10-Q (opens in a new tab)

Alkermes plc submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
Reed Joshua SVP, Chief Financial Officer	8 Oct 2026	Option exercise (M)	+9,164	—	Form 4 (opens in a new tab)
Reed Joshua SVP, Chief Financial Officer	8 Oct 2026	Tax withholding (F)	−4,069	$40.11	Form 4 (opens in a new tab)
Gaffin David Joseph EVP, CLO, Alkermes, Inc.	2 Oct 2026	Open-market sale (S)	−2,034	$41.03	Form 4 (opens in a new tab)
Gaffin David Joseph EVP, CLO, Alkermes, Inc.	3 Sep 2026	Open-market sale (S)	−2,034	$48.01	Form 4 (opens in a new tab)
Hopkinson Craig C. EVP R&D, Chief Medical Officer	1 Sep 2026	Option exercise (M)	+5,000	$24.59	Form 4 (opens in a new tab)
Hopkinson Craig C. EVP R&D, Chief Medical Officer	1 Sep 2026	Open-market sale (S)	−9,000	$46.99	Form 4 (opens in a new tab)
Nichols Christian Todd SVP, Chief Commercial Officer	17 Aug 2026	Open-market sale (S)	−7,576	$49.23	Form 4 (opens in a new tab)
snyderman nancy lynn MD Director	3 Aug 2026	Option exercise (M)	+44,472	$46.72	Form 4 (opens in a new tab)
snyderman nancy lynn MD Director	3 Aug 2026	Open-market sale (S)	−44,472	$50.35	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	29,235,739	3.254%
Vanguard Group Inc	12/31/2025	23,872,145	0.363%
Baker Bros. Advisors Lp	6/30/2026	10,012,267	0%
Vanguard Portfolio Management Llc	6/30/2026	9,490,818	-0.213%
State Street Corp	6/30/2026	9,160,575	-3.219%
Vanguard Capital Management Llc	6/30/2026	7,515,025	1.18%
Price T Rowe Associates Inc /Md/	6/30/2026	6,737,328	44.436%
Renaissance Technologies Llc	6/30/2026	6,460,928	4.878%
Geode Capital Management, Llc	6/30/2026	4,477,876	7.068%
Dimensional Fund Advisors Lp	6/30/2026	4,194,873	-7.242%

Previous close: 41.22 USD
Day range: 41.35 – 43.64 USD
52-week range: 27.00 – 55.67 USD
Volume: 2,713,433
Market cap: $7.21B
Average volume: 1,916,078
P/E ratio: 109.0
EPS (FY 2025, diluted): 1.43 USD
Shares outstanding: 167.76M
Beta (5Y monthly): 0.25

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:00 UTC· 2 days ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:07 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for ALKS yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.